These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 11252520

  • 1. Is amisulpride an 'atypical' atypical antipsychotic agent?
    Lecrubier Y.
    Int Clin Psychopharmacol; 2000 Dec; 15 Suppl 4():S21-6. PubMed ID: 11252520
    [Abstract] [Full Text] [Related]

  • 2. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
    Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B.
    J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185
    [Abstract] [Full Text] [Related]

  • 3. From pharmacological profiles to clinical outcomes.
    Kerwin R.
    Int Clin Psychopharmacol; 2000 Dec; 15 Suppl 4():S1-4. PubMed ID: 11252517
    [Abstract] [Full Text] [Related]

  • 4. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
    Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B.
    J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
    [Abstract] [Full Text] [Related]

  • 5. Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality.
    Möller HJ.
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1101-11. PubMed ID: 14642970
    [Abstract] [Full Text] [Related]

  • 6. Clinical implications of dopamine research in schizophrenia.
    Pani L.
    Curr Med Res Opin; 2002 Oct; 18 Suppl 3():s3-7. PubMed ID: 12418605
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers.
    Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G.
    Hum Psychopharmacol; 2002 Jan; 17(1):1-13. PubMed ID: 12404702
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Which role for amisulpride in rehabilitation of schizophrenic patients with acute exacerbation?
    Blin O.
    Encephale; 2000 Oct; 26 Spec No 1():7-11. PubMed ID: 11294060
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Consensus on the use of substituted benzamides in psychiatric patients.
    Racagni G, Canonico PL, Ravizza L, Pani L, Amore M.
    Neuropsychobiology; 2004 Oct; 50(2):134-43. PubMed ID: 15292667
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.